drugset / Trial / NCT01710033
A Study Of CP-690,550 In Stable Kidney Transplant Patients
RandomizedParallel-groupDouble-blindBasic science
Summary
This was a Phase 1 dose escalation study to evaluate the safety, tolerability and pharmacokinetics of 28-day treatment of CP-690,550 in stable renal allograft recipients. In Stage 1, ascending doses of CP-690,550 were to be administered sequentially to 3-4 cohorts of subjects. After Stage 1, one dose level was to be selected for dosing in an expanded cohort in Stage 2.
Timeline
- Start
- 2003-09
- Primary completion
- 2005-04
- Completion
- 2005-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tofacitinib | Small molecule | 5 mg | — |
| Subject | Tofacitinib | Small molecule | 15 mg | — |
| Subject | Tofacitinib | Small molecule | 30 mg | — |
Indications
No indication recorded.